GlassScriptPhysician profile
Jennifer Jo Whitehead
NPI 1942933049
$4,302.73
in general payments reported to CMS, 2019-2025
11 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $665 · 2024: $1,723 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.44 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,421.45 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $427.87 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $321.82 | 2022-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $299.79 | 2023-2025 | Veozah |
| Amgen INC. | $228.60 | 2023-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $163.27 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.87 | 2025 | Caplyta |
| Mayne Pharma Commercial LLC | $121.85 | 2025 | |
| Lilly USA, LLC | $121.84 | 2025 | Zepbound |
| Abbvie INC. | $37.75 | 2025 | |
| Organon LLC | $28.62 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.